Payment overview · 2025
General Payments
$136.72
5 reported records · 1 companies
Healthcare provider profile · identity verified
Harry Steven Klein, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · OMAHA, NE · NPI 1730117615
Verified facts
What the public records show
CMS Open Payments records show Harry Steven Klein, M.D. received $136.72 in general payments during 2025 across 5 reported records.
Amgen Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Otezla.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Otezla by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $136.72 | 100.0% | 5 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $136.72 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $96.46 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $23.83 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.43 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| OTEZLA otezla |
2025 | Otezla | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 698 | 139 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 466 | 103 |
| Levothyroxine Sodium | Levothyroxine Sodium | 389 | 81 |
| Atorvastatin Calcium | Atorvastatin Calcium | 374 | 89 |
| Tramadol Hcl | Tramadol Hcl | 350 | 62 |
| Trazodone Hcl | Trazodone Hcl | 341 | 81 |
| Duloxetine Hcl | Duloxetine Hcl | 337 | 59 |
| Amlodipine Besylate | Amlodipine Besylate | 336 | 75 |
| Gabapentin | Gabapentin | 329 | 77 |
| Celecoxib | Celecoxib | 310 | 61 |
| Omeprazole | Omeprazole | 302 | 65 |
| Methotrexate | Methotrexate Sodium | 291 | 70 |
| Meloxicam | Meloxicam | 243 | 61 |
| Losartan Potassium | Losartan Potassium | 240 | 57 |
| Tizanidine Hcl | Tizanidine Hcl | 228 | 54 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 218 | 49 |
| Pantoprazole Sodium | Pantoprazole Sodium | 203 | 40 |
| Alendronate Sodium | Alendronate Sodium | 181 | 39 |
| Lisinopril | Lisinopril | 164 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 151 | 33 |
| Metoprolol Tartrate | Metoprolol Tartrate | 150 | 22 |
| Alprazolam | Alprazolam | 144 | 25 |
| Montelukast Sodium | Montelukast Sodium | 138 | 30 |
| Furosemide | Furosemide | 134 | 34 |
| Allopurinol | Allopurinol | 131 | 24 |
| Mounjaro | Tirzepatide | 131 | 14 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 130 | 24 |
| Buspirone Hcl | Buspirone Hcl | 118 | 28 |
| Metformin Hcl | Metformin Hcl | 116 | 22 |
| Simvastatin | Simvastatin | 115 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 113 | 23 |
| Ezetimibe | Ezetimibe | 108 | 25 |
| Spironolactone | Spironolactone | 105 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 105 | 18 |
| Eliquis | Apixaban | 102 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 98 | 13 |
| Metformin Hcl Er | Metformin Hcl | 96 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 93 | 20 |
| Nabumetone | Nabumetone | 90 | 21 |
| Carvedilol | Carvedilol | 88 | 20 |
| Leflunomide | Leflunomide | 88 | 17 |
| Sertraline Hcl | Sertraline Hcl | 84 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 82 | 20 |
| Potassium Chloride | Potassium Chloride | 81 | 17 |
| Clonazepam | Clonazepam | 79 | suppressed |
| Pregabalin | Pregabalin | 66 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 64 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 61 | 21 |
| Bupropion Xl | Bupropion Hcl | 60 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 14 |
| Jardiance | Empagliflozin | 57 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 57 | suppressed |
| Mirtazapine | Mirtazapine | 55 | 12 |
| Folic Acid | Folic Acid | 54 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 52 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | suppressed |
| Sucralfate | Sucralfate | 46 | 12 |
| Enbrel Sureclick | Etanercept | 45 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 19 |
| Donepezil Hcl | Donepezil Hcl | 40 | suppressed |
| Methylprednisolone | Methylprednisolone | 39 | 34 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | 11 |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Baclofen | Baclofen | 37 | suppressed |
| Topiramate | Topiramate | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Trulicity | Dulaglutide | 36 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Glimepiride | Glimepiride | 35 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Cefdinir | Cefdinir | 34 | 30 |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 11 |
| Atenolol | Atenolol | 30 | suppressed |
| Famotidine | Famotidine | 28 | suppressed |
| Telmisartan | Telmisartan | 28 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 27 | suppressed |
| Estradiol | Estradiol | 26 | suppressed |
| Memantine Hcl | Memantine Hcl | 26 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | 12 |
| Orencia | Abatacept | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Finasteride | Finasteride | 24 | suppressed |
| Lamotrigine | Lamotrigine | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | suppressed |
| Savella | Milnacipran Hcl | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 20 | suppressed |
| Sulindac | Sulindac | 20 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 17 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Nyamyc | Nystatin | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Torsemide | Torsemide | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 16 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 15 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Indomethacin | Indomethacin | 14 | suppressed |
| Irbesartan | Irbesartan | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Benlysta | Belimumab | 12 | suppressed |
| Cosentyx Syringe | Secukinumab | 12 | suppressed |
| Dapsone | Dapsone | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Humira(Cf) | Adalimumab | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Sulfasalazine | Sulfasalazine | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Enbrel Mini | Etanercept | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Skyrizi Pen | Risankizumab-Rzaa | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $136.72 · 5 records | Amgen Inc. | EVENITY, OTEZLA, UPLIZNA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Otezla play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error